Type 1 Diabetes-A Proposal for Prevention & Intervention

1 型糖尿病 - 预防建议

• 批准号: 9268719
• 负责人: Antoinette M. Moran
• 金额: $ 58.16万
• 依托单位: UNIVERSITY OF MINNESOTA
• 依托单位国家: 美国
• 财政年份: 2009
• 资助国家: 美国
• 起止时间: 2009-09-30 至 2019-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9268719
• 关键词: Adaptive Immune System; Address; Adult; Affect; Ancillary Study; Anti-Inflammatory Agents; Anti-inflammatory; Area; Autoimmune Process; Autoimmunity; B-Lymphocytes; Beta Cell; Biological Markers; CTLA4-Ig; Cell Survival; Cell physiology; Child; Clinical; Clinical Trials; Collaborations; Combined Modality Therapy; Communicable Diseases; Data; Detection; Development; Diabetes Mellitus; Diabetes prevention; Diagnosis; Disease; Family; Fostering; General Population; Goals; Grant; Immune; Immune Tolerance; Immunization; Immunotherapy; Individual; Insulin; Insulin-Dependent Diabetes Mellitus; Interleukin-1 Receptors; International; Internet; Interruption; Intervention; Laboratories; MS4A1 gene; Malignant Neoplasms; Measurement; Methods; Midwestern United States; Minnesota; Natural History; Oral; Patients; Performance; Persons; Pharmaceutical Preparations; Pharmacologic Substance; Prevention; Prevention strategy; Prevention trial; Preventive Intervention; Process; Recording of previous events; Recruitment Activity; Regimen; Reporting; Research Personnel; Residual state; Risk; Risk Estimate; Running; Safety; Sampling; Site; Social Network; Societies; T-Lymphocyte; Testing; Universities; Vaccines; clinical research site; cost; follow-up; high risk; immunoregulation; novel strategies; novel therapeutics; prevent; public health relevance; research facility; screening

DESCRIPTION (provided by applicant): The Type 1 Diabetes TrialNet Consortium was initiated in 2001 following completion of its predecessor, the Diabetes Prevention Trial-Type 1 (DPT-1). This network consists of 14 US and 4 international clinical sites. In addition, there are more than 200 US affiliate sites which perform subject screening, a Central Coordinating Center, and several TrialNet-associated laboratories. The goals of the TrialNet consortium are to prevent or delay the onset of T1D, to test interventions aimed at decreasing beta cell destruction and/or enhancing beta cell survival in persons with T1D with residual beta cell function, and the performance of mechanistic studies. The University of Minnesota (UMN) has been a DPT-1/TrialNet Clinical Center since the beginning. Throughout this history, UMN has been highly productive and engaged, contributing intellectually to project development and reporting, and actively participating in all aspects of each TrialNet project. The aims of this renewal grant are to continue the tradition of UMN as a high-quality, high-performing TrialNet Clinical Center in the critical areas of project development, screening, recruitment, treatment, follow-up, and reporting; to increase screening rates for detection of subjects at high risk for development of T1D by further developing and supporting UMN affiliates and by exploring general population screening within new UMN research facilities at the Minnesota State Fair; and to foster collaborations with new T1D researchers in the Upper Midwest region.

描述（由申请人提供）：1型糖尿病试验网络联盟于2001年在其前身1型糖尿病预防试验（DPT-1）完成后成立。该网络由14个美国和4个国际临床中心组成。此外，还有200多个美国附属机构进行受试者筛选，一个中央协调中心和几个TrialNet相关实验室。TrialNet联盟的目标是预防或延迟T1 D的发作，测试旨在减少β细胞破坏和/或增强β细胞存活的T1 D患者残留β细胞功能的干预措施，以及机制研究的性能。明尼苏达大学（UMN）自成立以来一直是DPT-1/TrialNet临床中心。在这段历史中，UMN一直非常富有成效和参与，为项目开发和报告做出智力贡献，并积极参与每个TrialNet项目的各个方面。这笔更新补助金的目的是继续UMN作为一个高质量，高性能的TrialNet临床中心在项目开发，筛选，招聘，治疗，随访和报告的关键领域的传统;通过进一步发展和支持UMN附属机构以及在新的UMN研究中探索普通人群筛查，提高T1 D高风险受试者的筛查率明尼苏达州博览会的设施;并促进与上中西部地区新的T1 D研究人员的合作。